Clinical trials: Cancer Refractory
Myelodysplastic Syndromes, Acute Myeloid Leukemia
BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS
To assess the efficacy, and safety of BST-236 in patients unfit for intensive chemotherapy with AML or HR MDS that failed or relapsed following first line therapy
- Trial name
- NCT04827719
- Testing
- BST-236
- Where
- 17 sites in France
- Volunteers
- 38 people
- Sponsor
- Groupe Francophone des Myelodysplasies
Acute Myelogenous Leukemia
Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia
In patients with Core Binding Factors Acute Myelogenous Leukemia, the level of Minimal Residual Disease after chemotherapy is predictive of relapse.
- Trial name
- DasaCBF (NCT02113319)
- Testing
- dasatinib
- Where
- France
- Volunteers
- 27 people
- Sponsor
- University Hospital, Angers
Prostatic Neoplasms
Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer
This is a multi-center, open-label, Phase 1/2 study of SU011248 (sunitinib malate, SUTENT) in combination with docetaxel and prednisone for the first-line treatment of metastatic hormone-refractory prostate cancer (mHRPC).
- Trial name
- NCT00137436
- Testing
- Docetaxel, Prednisone, SU011248
- Where
- 24 sites in United States
- Volunteers
- 93 people
- Sponsor
- Pfizer
Relapsed/Refractory Glioma
A Prospective, Single-arm Clinical Study on the Safety and Efficacy of Ivoximab Combined With Temozolomide in the Treatment of Relapsed/Refractory Glioma
This study is a prospective, single-arm clinical trial aimed at evaluating the safety and efficacy of ivoximab combined with temozolomide in the treatment of relapsed/refractory glioma.
- Trial name
- NCT07599371
- Testing
- Ivoximab 20 mg/kg, ivgtt, Q4W, Temozolomide (TMZ)
- Where
- China
- Volunteers
- 29 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Lymphoma
CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma
In this single-center, single-arm,prospective, open-label, phase 1/2 study, the safety and efficacy of autologous CD70 targeted chimeric antigen receptor modified T (CAR-T) cell therapy will be evaluated in patients with CD70…
- Trial name
- NCT05948033
- Testing
- CD70-targeting CAR-T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Prostate Cancer
Docetaxel, Doxorubicin, and Prednisone in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy, such as docetaxel, doxorubicin, and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00416533
- Testing
- docetaxel, doxorubicin hydrochloride, prednisone
- Volunteers
- 47 people
- Sponsor
- Wake Forest University Health Sciences
Unspecified Adult Solid Tumor, Protocol Specific
MEN-10755 in Treating Adults With Recurrent or Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of MEN-10755 in treating adults who have recurrent or…
- Trial name
- NCT00003028
- Testing
- sabarubicin
- Where
- 49 sites in Austria, Belgium and 12 more
- Volunteers
- 5 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Recurrent Small Cell Lung Cancer
CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
This pilot clinical trial studies CPI-613 (6,8-bis[benzylthio]octanoic acid) in treating patients with relapsed or refractory small cell lung cancer.
- Trial name
- NCT01931787
- Testing
- 6,8-bis(benzylthio)octanoic acid
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Wake Forest University Health Sciences
Non Small Cell Lung Cancer, Advanced Solid Tumor
TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies
A phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TGRX-1942 in patients with advanced solid tumor and/or relapsed or refractory hematological malignancies
- Conditions
- Non Small Cell Lung Cancer, Advanced Solid Tumor, Hematologic Malignancy
- Trial name
- NCT06484816
- Testing
- TGRX-1942
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shenzhen TargetRx Co., Ltd.
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and cyclophosphamide, and radiation therapy before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00255684
- Testing
- graft-versus-tumor induction therapy, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Rochester
Fallopian Tube Cancer, Ovarian Cancer
S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have refractory…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00053833
- Testing
- irinotecan
- Where
- 100 sites in United States, Canada
- Volunteers
- 2 people
- Sponsor
- SWOG Cancer Research Network
Multiple Myeloma
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
The purpose of this study is to evaluate the efficacy and safety of pomalidomide monotherapy in subjects with refractory or relapsed and refractory multiple myeloma who were enrolled in study CC-4047-MM-003 (NCT01311687) and…
- Trial name
- NCT01324947
- Testing
- pomalidomide
- Where
- 91 sites in Australia, Belgium and 13 more
- Volunteers
- 74 people
- Sponsor
- Celgene
B-cell Non Hodgkin Lymphoma
Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies
This is a Phase 1 interventional, single-arm, open- label, treatment study designed to evaluate the safety of h20.19 CAR T cells in patients with B-cell malignancies that have failed prior therapies.
- Trial name
- NCT07335328
- Testing
- 1 X 10^6 cells/kg, 2.5 X 10^6 cells/kg, Dose expansion: The maximum tolerated dose of CAR-T cells
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Medical College of Wisconsin
Advanced or Refractory Leukemia, Lymphoma, Multiple Myeloma
Bioengineered Allogeneic Immune Cells (AlloStim) Not Requiring HLA Donor Match for Blood Cancers
This phase I/II clinical investigation is designed to determine the safety and anti-tumor effects of intravenous administration of the experimental immunotherapy drug, called AlloStim.
- Trial name
- NCT00861965
- Testing
- AlloStim-8
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Mirror Biologics, Inc.
Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
The investigators want to find out whether or not giving patients who have relapsed or refractory multiple myeloma (MM) the experimental medication combination iberdomide, carfilzomib, daratumumab, and dexamethasone (Iber-KDd)…
- Trial name
- Iber-KDd (NCT05896228)
- Testing
- Iberdomide, Carfilzomib, Daratumumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Benjamin T Diamond, MD
Hormone-refractory Prostate Cancer
Analyze the Predictive Value of Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Prostate Cancer
Prostate cancer is the most common non-skin tumor diagnosed in men and the second leading cause of cancer death in men in Western countries.
- Trial name
- PREMIERE (NCT02288936)
- Testing
- Enzalutamide
- Where
- 16 sites in Spain
- Volunteers
- 98 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Anemia, Recurrent Multiple Myeloma
Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
This phase I trial studies the side effects and best dose of wild-type reovirus when combined with carfilzomib and dexamethasone in treating patients with multiple myeloma that has come back following treatment (relapsed) or does…
- Conditions
- Anemia, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Trial name
- NCT02101944
- Testing
- Carfilzomib, Dexamethasone, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Kidney Cancer
Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer
RATIONALE: Giving low doses of chemotherapy and radiation therapy before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Breast Cancer, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00365287
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Volunteers
- 148 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Unspecified Childhood Solid Tumor, Protocol Specific
Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of combining carboplatin and irinotecan in treating…
- Trial name
- NCT00024284
- Testing
- carboplatin, irinotecan hydrochloride
- Where
- 7 sites in United States, Canada
- Sponsor
- Bristol-Myers Squibb
Multiple Myeloma
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to identify the recommended Phase 2 regimen(s) (RP2R[s]) and schedule for the study treatment (Part 1), to characterize the safety of the RP2R(s) for the study treatment (Part 2) and to evaluate the…
- Trial name
- RedirecTT-1 (NCT04586426)
- Testing
- Talquetamab, Teclistamab
- Where
- 40 sites in United States, Australia and 5 more
- Volunteers
- 228 people
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.